Melanoma, Urothelial Carcinoma
Conditions
Brief summary
This study will assess the safety, tolerability and efficacy of every-2-week dosing of QLF31907 injection in patients with advanced melanoma and urothelial carcinoma.
Detailed description
This study is divided into two parts. The first part is the safety and tolerability observation period, mainly observing the safety and tolerability of QLF31907. The second part is mainly the efficacy observation period, further evaluating the efficacy and safety of QLF31907 in patients with advanced melanoma and urothelial carcinoma.
Interventions
DRUGQLF31907
Intravenous infusion once every two weeks. The dose administered in part 2 will depend on the outcome of part 1.
Sponsors
Qilu Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subjects voluntarily participated and signed a written informed consent form 2. Age ≥ 18 years, male or female 3. ECOG performance status of 0 or 1 4. Expected life-expectancy ≥ 3 months 5. Histologically confirmed diagnosis of locally advanced or metastatic unresectable melanoma or urothelial carcinoma, failed or intolerant or rejected to standard therapy 6. Patients must have at least one measurable lesion according to RECIST v1.1 7. Adequate organ function prior to QLF31907 administration 8. All subjects of reproductive potential must agree to use an effective method of contraception during the study and for 180 days after the last dose, and women of reproductive age must have a negative blood pregnancy result within 7 days prior to the first dose.
Exclusion criteria
1. Prior treatment with 4-1BB agonist or 4-1BB recombinant fusion protein 2. Known to be allergic to any excipients of QLF31907 or a history of severe allergic reactions to other monoclonal antibodies 3. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation, or autologous stem cell transplantation within 180 days 4. Known history of cytotherapy or antitumor vaccine or other antitumor therapy or surgical treatment of main organs within 4 weeks 5. Known history of systemic glucocorticoid therapy or other immunosuppressants within 14 days 6. Active central nervous system (CNS) metastases 7. Known history of other active malignant tumor within 3 years, unless completely cured 8. With uncontrolled or clinically symptomatic pleural, pericardial or abdominal effusions 9. An active infectious disease requiring intravenous antibiotic therapy 10. Failure to recover to grade 1 from adverse reactions due to prior treatment according to CTCAE v5.0 11. An active autoimmune diseases or known history of ≥ grade 3 irAE due to prior immunotherapy 12. Known history of active hepatitis B/C infection, severe cardiovascular and cerebrovascular disease, idiopathic pulmonary fibrosis, pneumoconiosis, asbestosis, hepatitis (nonalcoholic steatohepatitis, alcoholic or autoimmune hepatitis), cirrhosis, active tuberculosis, active syphilis, HIV infection 13. Poorly controlled respiratory, circulatory or endocrine diseases 14. Known history of drugs abuse, alcoholism, neurologic or psychiatric disorders 15. Patients who are breastfeeding 16. Other serious physical or psychiatric illnesses or laboratory abnormalities that may increase the risk of participating in the study, or interfere with the results of the study, and patients who are not suitable for participation in this study in the opinion of the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (part 1)Dose-limiting toxicity(DLT) | 28days |
| (part 2) Objective response rate(ORR) | up to 2 years |
Secondary
| Measure | Time frame |
|---|---|
| (part 2) Overall survival(OS) | up to 2 years |
| (part 2) Safety index: adverse event(AE), serious adverse event (SAE), treatment-related adverse event(TRAE) | up to 2 years |
| (part 2) Positive rate of anti-drug antibody(ADA) | up to 2 years |
| (part 2) Maximum observed plasma concentration (Cmax) | up to 2 years |
| (part 2) Progression-free survival(PFS) | up to 2 years |
Countries
China
Contacts
Primary ContactJun Guo, MD
Backup ContactLu Si, MD
Outcome results
None listed